dc.contributor.authorLee, Sie Huey
dc.contributor.authorTeo, Jeanette
dc.contributor.authorHeng, Desmond
dc.contributor.authorZhao, Yanli
dc.contributor.authorNg, Wai Kiong
dc.contributor.authorChan, Hak-Kim
dc.contributor.authorTan, Reginald B. H.
dc.date.accessioned2016-01-13T03:05:15Z
dc.date.available2016-01-13T03:05:15Z
dc.date.issued2014
dc.identifier.citationLee, S. H., Teo, J., Heng, D., Zhao, Y., Ng, W. K., Chan, H.-K., et al. (2014). Steroid-Decorated Antibiotic Microparticles for Inhaled Anti-Infective Therapy. Journal of Pharmaceutical Sciences, 103(4), 1115-1125.en_US
dc.identifier.issn0022-3549en_US
dc.identifier.urihttp://hdl.handle.net/10220/39686
dc.description.abstractDespite advances in vaccination and antimicrobial therapy, community-acquired pneumonia (CAP) remains as a leading cause of morbidity and mortality worldwide. As the severity of CAP has been linked to the extent of inflammation in the body, adjunctive therapeutic measures aimed at modulating the immune response have therefore become increasingly attractive in recent years. In particular, for CAP patients with underlying medical conditions such as chronic obstructive pulmonary disease (COPD), a steroid–antibiotic combination will no doubt be a useful and timely therapeutic intervention. Unfortunately, no combined steroid–antibiotic dry powder formulation is available commercially or has been reported in the academic literature. The aim of this work was hence to develop a novel steroid–antibiotic dry powder inhaler formulation [ciprofloxacin hydrochloride (CIP) and beclomethasone dipropionate (BP)] for inhaled anti-infective therapy. The spray-dried powder was of respirable size (d50 of ∼2.3 μm), partially crystalline and had BP preferentially deposited on the particle surface. Favorably, when formulated as a binary mix, both CIP and BP showed much higher drug release and fine particle fractions (of the loaded dose) over their singly delivered counterparts, and had robust activity against the respiratory tract infection-causing bacteria Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus.en_US
dc.description.sponsorshipASTAR (Agency for Sci., Tech. and Research, S’pore)en_US
dc.format.extent33 p.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesJournal of Pharmaceutical Sciencesen_US
dc.rights© 2014 Wiley Periodicals, Inc. This is the author created version of a work that has been peer reviewed and accepted for publication by Journal of Pharmaceutical Sciences, Wiley Periodicals, Inc. It incorporates referee’s comments but changes resulting from the publishing process, such as copyediting, structural formatting, may not be reflected in this document. The published version is available at: [http://dx.doi.org/10.1002/jps.23874].en_US
dc.subjectdry powder inhaler; community-acquired pneumonia (CAP); chronic obstructive pulmonary disease (COPD) ;corticosteroids; combinatorial therapy; spray drying; aerosols;pulmonary drug delivery; formulation; antiinfectivesen_US
dc.titleSteroid-Decorated Antibiotic Microparticles for Inhaled Anti-Infective Therapyen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Materials Science and Engineeringen_US
dc.contributor.schoolSchool of Physical and Mathematical Sciencesen_US
dc.identifier.doihttp://dx.doi.org/10.1002/jps.23874
dc.description.versionAccepted versionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record